Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
July 29, 2021
Earnings Call Speaker Segments
Larry Keusch
executiveThanks, Dexter. Hello, everyone, and good morning. It's great to have you join us for the Teleflex Incorporated Second Quarter 2021 Earnings Conference Call. You can find the press release and the slides that go with this call on our website, www.teleflex.com. Just a reminder that this call is being webcast on our site, and a replay can be accessed by calling (800) 585 to 8367, or if you're outside the US, (416) 621 to 4642, using passcode 5188749. On the line with us today are Liam Kelly, our Chairman, President and Chief Executive Officer, and Thomas Powell, Executive Vice President and Chief Financial Officer. Liam and Tom will share prepared remarks, and after that, we'll move to Q&A. Before we get started, I want to remind everyone that certain matters we'll discuss on this conference call will include forward-looking statements about future events, as described in our slides. Please be aware that these statements are indeed forward-looking and involve risks and uncertainties, so actual events or results could differ materially. Among the factors that might cause actual results or events to differ materially are those mentioned in today's press release and in our SEC filings, including our Form 10-K, which you can access on our website. Also, please keep in mind that although we've offered commentary on intra-quarter business performance during recent earnings calls to give extra details and insights about trends, we don't plan to offer that kind of commentary on today's call or in connection with future earnings calls. With all that said, I'll hand the call over to Liam for his remarks.
Liam Kelly
executiveLarry, thank you, and a good morning to all of you; I'm glad to be here with you today. Our results for the second quarter make us very happy, and they came in above the forecast we shared during the call about our first quarter earnings, which mirrors how the company's dependable base business and inventive growth drivers performed, set against COVID-19 difficulties that varied in severity around the world. For most of our product families globally, constant currency growth was recorded versus the second quarter of 2019. As we had expected, we saw better underlying utilization patterns in those product categories hit hardest by nonemergent procedures being postponed, above all interventional urology, interventional and surgical. UroLift gives us reason for optimism, since momentum keeps building there, producing 26% constant currency revenue growth measured against the first quarter of 2021. In the second quarter, our Americas, Asia and OEM segments turned in solid performances, with constant currency revenues rising above 2019, while EMEA has now recovered to 2019 revenue levels. As we expected, recovery in the Americas and Asia is happening faster than in EMEA. Even though COVID-19 still brings uncertainty, we keep expecting our revenue results to get better as we progress through the rest of 2021; in the second quarter, operating margin improved versus 2020 and 2019 in the comparable periods, and this came from gross margin along with disciplined expense control. Because we kept making headway on margin expansion in 2021, we have been able to raise directed investments toward growth drivers, which matters greatly to our long-term strategy of strengthening durable growth. With the second quarter results being so strong, we are holding our constant currency revenue guidance steady, which now reflects a $28 million to $32 million sales headwind tied to the June 28 initial close of the respiratory products divestiture, something our prior guidance did not account for. Considering our outlook for the second half of 2021 and our margin improvement in the second quarter, we are raising our 2021 earnings per share guidance to a range of $12.90 to $13.10, up from the $12.65 to $12.85 we previously guided. We keep carrying out our strategy of driving durable growth through investment in organic growth opportunities, margin expansion and capital deployment for M&A. Now let me turn to a more detailed look at our second quarter results. Revenue in the second quarter reached $713.5 million, which is 21% higher year-over-year on a constant currency basis and 6.8% above the comparable period in 2019. Contributions from interventional, anesthesia, surgical and interventional urology powered the year-over-year increase, which was partly offset by unfavorable year-over-year comparisons stemming from stronger demand for our vascular access and respiratory products in quarter 2 2020 tied to COVID-19. We are also happy with our second quarter gross and operating margins, which improved sequentially over a strong Q1. For Teleflex as a pure-play medical device company, Q2 adjusted and operating margins reached new high watermarks, a promising indicator for our longer-term profitability goals. Adjusted earnings per share for the second quarter came to $3.35, up 73.6%, and beat what we had expected internally. The better-than-expected earnings came from health care utilization bouncing back in Q2, along with stronger volumes, slight price gains, and careful management of operating costs. All in all, I'm quite pleased with how we performed financially in the second quarter, which shows what our diversified worldwide product lineup can do, and it also points to strides we're making toward our longer-term margin goals. Now let's take a closer look at revenue. I'll start by going over revenues for our reportable segments; and unless I say otherwise, the growth rates I mention are calculated on a constant currency basis. In the second quarter, Americas revenues came to $414.8 million, up 31.8% from a year earlier and 10.8% above the same period in 2019. The growth came from a rebound in procedures after the disruption experienced earlier in the year, with especially strong results in interventional urology, surgical and interventional. EMEA revenues reached $157.1 million, a rise of 8.4% year-over-year, and were flat versus 2019 levels. EMEA got a boost from a favorable COVID-related comparison as procedures improved from a year ago while countries throughout the region kept reopening. Now on to Asia. Revenues totaled $80.6 million, up 10.3% year-over-year and in line with what we saw in the first quarter of 2021. Asia rose 1.7% compared with 2019. Notably, we recorded solid double-digit growth in China and high single-digit growth in Japan, which more than made up for declines in Southeast Asia. And finally, our OEM business, representing about 9% of total sales, grew 6.9% year-over-year to $61 million in the second quarter. OEM was up 6.5% versus the comparable period in 2019. After a 17.1% decline in the first quarter of 2021, this business rebounded as customers increased orders amid signs of rising health care utilization. We still anticipate sequential growth improvement through the second half of 2021, helped in part by additional capacity. Let's turn now to a discussion of our second quarter revenues by global product category. As with my earlier comments on our reportable segments, commentary on global product category growth will also be given on a constant currency basis. As a reminder, there were no meaningful differences in year-over-year selling days in the second quarter. Beginning with Vascular Access. Second quarter revenues fell 2.1% to $167.7 million. Even though we're up against tough year-over-year comparisons in Vascular Access, because of the higher demand seen in quarter 2 2020 tied to COVID-19, our innovative products continued to perform strongly. Our PICC portfolio did well, with growth of more than 30% year-over-year; we keep investing behind our differentiated PICC portfolio and keep gaining share. Interosseous was also strong in the second quarter, with growth of 15.5% year-over-year. Moving to Interventional. Second quarter revenue was $112.1 million, which climbed 30.9% year-over-year. The gain stemmed from a recovery in certain nonemergent procedures on a year-over-year basis. Our proprietary large-bore closure product, MANTA, posted a 160% increase compared with the prior year, leaving us strongly positioned to capture 8% share during 2021 within a market opportunity worth $200 million to $300 million. Now shifting to Anesthesia. Revenue for the second quarter came in at $95.4 million, a rise of 38.8% versus a year earlier. Z-Medica accounted for about 60% of that growth, with the business still on pace toward our $60 million to $70 million revenue expectation for 2021, though this was partly offset by weaker sales of tracheostomy products. After adjusting for FX and the Z-Medica acquisition, Anesthesia's underlying growth in the second quarter was roughly 16% compared with the prior year. Z-Medica's integration is proceeding very well, and we are pleased with the progress we are making. In our Surgical business, revenue reached $98.2 million, which represents 39% growth versus a year earlier. This revenue increase came from sales of our metal and polymer ligation clips and instruments, as elective surgical procedures keep recovering. Regarding Interventional Urology, second quarter revenue totaled $92.2 million, up 129.4% year-over-year and 35.6% above the second quarter of 2019, which reflects a return toward more normalized growth; we are encouraged by business trends, with physicians staying engaged in using UroLift across all care settings and patients increasingly pursuing treatment for BPH symptoms. Our DTC momentum continues to be solid, and we remain comfortable with our 30%-plus revenue growth objective for UroLift in 2021.
Liam Kelly
executiveFinally, in our Other segment, which includes products for respiratory and urology care, revenue dropped 9.9%, landing at $86.9 million. This decline stems from difficult comparisons against last year, when COVID-driven demand for respiratory products in the Americas and EMEA was strong. That covers my overview of how revenue performed in the second quarter. Now I'll turn to some updates on the clinical and commercial side. In Q2, we provided training to 118 urologists, and we remain on track to reach our target of training between 450 and 500 urologists during 2021. Our 2021 DTC program continues to move forward. Through this year's campaign, we are fine-tuning which networks we use, refreshing the creative, and aligning with social media initiatives to maximize the overall impact. Given how much awareness the DTC campaign has generated, we decided to put additional money into the second half of 2021 to connect with this market that remains underpenetrated. In the U.S., we view DTC as a catalyst for UroLift that will play out over multiple years, because market adoption and patient awareness are both still at very early stages. Actually, when it comes to minimally invasive BPH treatment, UroLift is leading the way, and for the first time in recent years, a BPH brand is reaching patients directly in a way that truly matters. Moving now to UroLift 2. Our U.S. rollout is fully underway, and it matches the timing we had expected. Our expectation remains that the majority of physician customers will have made the switch to UroLift 2 by the end of 2022. The reasons behind this are better visualization, a reduced need for storage space, and increased manufacturing capacity. Once the revenue base has completely converted, we remain in a position to achieve significant margin expansion. Turning to Japan, a reimbursement decision is still expected in 2021, and we view the approximately 2 billion addressable market as another growth driver that will act as a favorable catalyst moving forward. The July MHLW meeting did not include a review of our submission, and we now expect a review in September, followed by a launch in the fourth quarter of 2021. Our outlook for UroLift revenue in Japan remains unchanged. We expect growth to begin in 2022, with only a small amount coming through in 2021. Turning to U.S. reimbursement, CMS put out its proposed physician fee schedule for calendar 2022 on July 13. Under that proposal, reimbursement rates for UroLift performed in the physician office setting fell 19% to 21% compared with the year before. I want to flag a couple of points. One, these proposed cuts to office-based procedures wouldn't go into effect until January 1, 2022, meaning our 2021 outlook is unaffected. Two, the proposed reductions were broad-based, affecting a variety of office-based procedures spanning many surgical specialties, and they weren't unique to UroLift. Third, our clinical evidence remains a differentiator—the LIFT pivotal trial plus real-world studies—and it distinguishes us from other ways of treating BPH while supporting UroLift uptake. As for what comes next, Teleflex will use the public comment period to talk with key stakeholders and restate what UroLift offers for BPH treatment. Our hope is that CMS will acknowledge the value of preserving patient access to safe, effective, less invasive options like UroLift in lower cost sites of care, such as the physician's office. We expect the final rules to come out in the fourth quarter of 2021. On a separate note, CMS released the proposed outpatient prospective payment system rates on July 19. The proposed reimbursement amounts for UroLift in hospital outpatient departments and ambulatory surgery centers are what these figures address. Specifically, compared with 2021, the suggested 2022 payments for UroLift rose by roughly 3%. Those who follow Teleflex are aware that roughly two-thirds of UroLift revenue comes from the ASC and outpatient environments. Now, moving to the following slide, which provides a clinical update on UroLift. A presentation took place on July 9 at the European Association of Urology Meeting, featuring the biggest analysis of U.S. Medicare and commercial claims covering 4 BPH procedures. Reimbursement claims spanning 2015 through 2019 formed the basis of this study, which assessed surgical retreatment and postoperative complications experienced by patients who had undergone TURP, GreenLight laser, Rezum and UroLift procedures. Looking at data collected four years on from the initial procedure, rates of surgical retreatment came out similar across UroLift, TURP and GreenLight laser, whereas Rezum showed the highest figure. Then, when measured 300 days following treatment, the fewest complications overall appeared with UroLift, and Rezum again ranked worst on that measure. Because these findings carry statistical significance, they show that UroLift works well when lined up against alternative BPH therapies in everyday clinical practice. Our plan is to keep strengthening the clinical evidence we've built, and that should support UroLift's position as the top minimally invasive option for treating BPH while going after a worldwide market chance worth billions of dollars. With that, let me give you some context on the respiratory divestiture. Aligning with our plan to pursue lasting expansion and a rigorous evaluation of our portfolio, we closed the first stage of selling off a major share of our respiratory offerings to Medline Industries on June 28. This deal brought in $286 million in cash, minus $12 million in working capital that stayed with us rather than going to Medline. The product lines we sold had produced $139 million in revenues during 2020, as we mentioned before. Going forward, shedding these respiratory assets will enhance our organic growth rate and margins in the long run, while putting us in a stronger spot for allocating internal resources and concentrating on our main growth drivers. That wraps up my prepared comments. At this point, I'll hand things over to Tom, who will walk us through the second quarter's financial results in greater detail. Tom?
Tom Powell
executiveThanks, Liam, and good morning, everyone. Now that the company's revenue performance has been covered, I'll begin with gross profit. For the second quarter, adjusted gross margin reached 59.9%, an increase of 600 basis points compared with the same period last year. This margin improvement came from product and regional mix, as well as gains related to cost improvement initiatives, favorable pricing impacts, M&A and foreign exchange, though these were partly offset by logistics and distribution expense. Adjusted operating margin for the second quarter was 28.2%, up 640 basis points year over year, mainly because of the gross margin improvement and disciplined expense management, with investment in the business providing a partial offset. Thanks to a stronger top line and better operational performance, our gross margin to operating margin conversion came in at the more customary 1:1 ratio for Q2. Net interest expense for the quarter was $15.9 million, up from $15.5 million during the same stretch last year. As we noted earlier, during Q2 we sent a redemption notice to holders of the $400 million aggregate principal amount of 4 and 7/8% senior notes due in 2026 that remained outstanding. Redemption took place on June 1, 2021, with the revolving credit agreement borrowings and available cash covering the cost. For Q2 of 2021, our adjusted tax rate stood at 14.4%, versus 15.8% a year earlier. When you look at our adjusted tax rate, the decline compared to a year ago comes mainly from where our profits are being earned geographically, plus we saw a bigger benefit tied to stock-based compensation than we did in the same period last year. Down at the bottom line, adjusted earnings per share for the second quarter came in at $3.35, which is up 73.6%. That figure includes roughly $0.16 that we estimate came as a favorable boost from foreign exchange. Now let me move on to a few balance sheet and cash flow items. During the first six months of 2021, operations generated $265 million in cash flow. In the same stretch a year earlier, that number was $134 million, so we're looking at an increase of $131 million year over year. This gain came mainly from strong operational performance, reduced payments tied to contingent consideration, and smaller outlays for payroll and benefits. Those positives were partly offset by negative working capital movements and increased tax disbursements. All in all, our balance sheet is still in solid condition. When the second quarter closed, we held $361.8 million in cash, compared with $375.9 million at the close of 2020's fourth quarter. During Q2, we reduced debt by $75 million, and net leverage stood at roughly 2.5x when the quarter ended. After the quarter closed, we used money largely generated from the first closing of the respiratory business divestiture to make a $259 million payment against our revolving credit facility. Now I'll turn to 2021 guidance. Let's begin with revenue. For 2021, our guidance on constant currency revenue growth stays where it was — somewhere between 8.5% and 9.75% compared with last year. Something to keep in mind: because the second quarter came in so strong on sales, we were able to absorb a revenue headwind of $28 million to $32 million during the back half of the year related to the respiratory divestiture, and that headwind wasn't something we had factored into the guidance we gave previously. When you're adjusting your model, remember that the respiratory products we divested fall under our other revenue category. And one more thing — for historical revenues tied to the divested respiratory products, take a look at the investor slide deck. Looking at what will drive our 2021 revenue growth on a constant currency basis, the biggest pieces are expected to be interventional urology along with our interventional, surgical and anesthesia products. Where Interventional Urology is concerned, nothing has changed in our view that 2021 will bring growth of at least 30%; likewise, we still anticipate that buying Z-Medica will contribute between $60 million and $70 million of sales during 2021. Now on to currency. We see foreign exchange rates providing a tailwind of roughly 2% to reported revenue growth. As a result, our expectation for as reported revenue remains an increase of between 10.5% and 11.75% compared with 2020. In dollar terms, that works out to somewhere between $2.804 billion and $2.835 billion. With that, let me offer a few comments on our margin outlook. For 2021, our adjusted gross margin outlook is moving up to somewhere between 59.25% and 59.75%. Compared with what we told you before, that's 100 basis points better at the bottom of the range and 50 basis points better at the top. The main drivers of this expected gross margin improvement are a favorable mix of products that carry higher margins — interventional urology, interventional access and surgical among them — along with gains from manufacturing productivity initiatives and the benefits of footprint restructuring programs we announced earlier, though inflation will partly offset those factors. As for Z-Medica, our assumption that this acquisition contributes roughly 50 basis points to gross margin in 2021 has not changed. On adjusted operating margin, our 2021 guidance is going up, and the new range is 26.75% to 27.50%. Compared with what we previously told you, that's 75 basis points higher at the bottom and 50 basis points higher at the top. Most of this improvement in adjusted operating margin will be driven by gross margin and leverage, though that will be partly offset by two things: higher spending we expect in the back half of 2021 as things move toward a more normalized environment, and additional strategic investments in UroLift and MANTA. Continuing further down the income statement, our 2021 interest expense projection now sits between $60 million and $62 million, compared with the earlier forecast of $61 million to $63 million. This lower figure is mainly due to less debt, made possible by money received from the respiratory divestiture. Regarding taxes, our adjusted tax rate should still land somewhere between 13% and 13.5%, and the respiratory divestiture's effect comes in at 4.875%. Taking all of this into account, we're lifting our 2021 adjusted EPS guidance to between $12.90 and $13.10, reflecting growth of 20.9% to 22.8% compared with last year. It's a pleasure to be in a position to lift our EPS outlook by $0.25, and at the same time absorb the $0.10 to $0.15 of earnings-per-share dilution tied to the respiratory divestiture that our earlier guidance hadn't accounted for. That wraps up what I had prepared. At this point I'd like to hand things back to Liam for some closing thoughts. Liam?
Liam Kelly
executiveThanks, Tom. To wrap up, I want to call out 3 main points from the quarter. First, we turned in a robust second quarter, with results on both the top and bottom lines coming in ahead of what we had told you to expect on the Q1 call. Second, our growth path continues to give us confidence, since most of our product families worldwide grew in constant currency terms versus the second quarter of 2019. Third, we held our revenue forecast steady while lifting our adjusted margin and earnings per share guidance for 2021, even with the challenges tied to the respiratory divestiture, which our earlier guidance had not factored in; to sum up, we are pleased with how we performed this quarter and with the growth chances ahead of us. Given the respiratory divestiture closed early in the third quarter, our leverage came to 2.3x, leaving us well placed when it comes to balance sheet flexibility. We will keep honoring what we owe to patients, clinicians, communities and, naturally, our shareholders. That wraps up my prepared remarks. At this point I'd like to hand the call back to the operator for Q&A.
Matt Taylor
analystFirst off, I'd like to hear about what you're observing with UroLift trends. Could you walk us through any patterns from the quarter? After that, please address how confident you are in restating the UroLift guidance for the full year, plus any detail on the cadence we ought to anticipate across the remaining months.
Liam Kelly
executiveSure thing, Matt, and I appreciate the question. As Larry mentioned during his opening remarks, we won't be diving into intra-quarter specifics for this period. That said, let me share this: to start, what we witnessed with UroLift in Q2 has us quite encouraged; we are affirmatively restating our expectation of 30%-plus growth for UroLift. Also, the nearly 130% growth achieved this quarter and the 26% sequential quarter-over-quarter increase have us genuinely pleased. Those who follow UroLift will remember that in Q1, on a days-adjusted basis, it expanded roughly 30% against 2019; then during Q2, growth compared with 2019 in fact sped up to approximately 36%. We also keep anticipating that total dollar revenues per UroLift will go on climbing in Q3 relative to Q2 and once more in Q4 relative to Q3. So that's an encouraging, favorable update on UroLift, Matt.
Matt Taylor
analystAlso, may we hear your general perspective regarding the reimbursement modification, plus your work on securing an alternative result in the final rule? And assuming the most unfavorable outcome persists and those reductions hit the office setting, what then?
Liam Kelly
executiveHonestly, Matt, we are eager to sit down with CMS so we can gain a clearer picture of what they were aiming for when they applied cuts this sweeping across more than 600 surgical procedures carried out in office-based locations. Our aim will be to present the strong clinical evidence backing UroLift along with the health care economics evidence, which happens to be quite persuasive too. I'm confident they'll pay attention to the possible unintended effect of certain procedures shifting into settings with higher care costs. In our view, the timing of this proposed modification could be unwise, coming when nearly all government entities are working to encourage procedural recovery after COVID and are pushing for that recovery toward lower-cost locations, which patients likewise perceive as carrying less risk of catching COVID. Therefore, we intend to work with the important stakeholders, among them additional device industry participants, trade organizations, physician associations, and patient advocacy organizations. Our approach, Matt, will hinge on the final ruling and what choices we then make going forward. Furthermore, we trust CMS will take heed, since such a wide range of comments is set to arrive concerning this specific ruling.
Cecilia Furlong
analystLiam, I'd like to stick with UroLift for a moment. I'm just wondering if you could address the patients who are giving UroLift a try while COVID is going on? What recent contributions have looked like, and are there any patterns on the service side of UroLift? Then, separately, what do you anticipate from DTC contributions over the second half of this year?
Liam Kelly
executiveSure. Appreciate it, Cecilia. On the question of where procedures happen, roughly 30% have historically taken place in the office, while the rest occurred elsewhere — the ASC and the hospital. As we moved through COVID, which addresses the other piece of what you asked, office procedures ticked up somewhat; now that we're emerging on the far side of COVID, that's settling back down toward a more typical level. Turning to DTC, we feel quite encouraged by how DTC has performed — enough so that we've raised our investment in it for the back half of the year. Our earlier expectation was roughly 125% of the impressions in 2021 compared with 2020. Given this larger investment, we now believe we'll reach 150%-plus the number of impressions we'll capture. I spent a week traveling with the sales team, meeting urologists. I sat down with more than 20 urologists. All — and this is purely anecdotal, I recognize that. But <<inaudible>> a single urologist told me people have walked into their practice — whether a hospital, ASC or an office — citing the ads they caught on television or that reached them on Facebook, and asking the urologist about UroLift because of that. So that's really encouraging, and we still view it as a great return on our investment. As a result, we're putting additional dollars in during the back half of the year.
Cecilia Furlong
analystGreat. And then also regarding gross margins. In terms of your second half, might you speak to what's implied for either UroLift 2 conversion or OEM contributions, plus geographic mix?
Liam Kelly
executiveSo I'll just address UroLift, and then I'll have Tom weigh in. So we expect the UL2 conversion to wrap up by the close of 2022. We're now in full ramp as we move toward the latter part of the year. I'm happy to say that we continue to expect that we'll gain a full 4 percentage points of margin from that switch to the UL2. And so, that would contribute roughly 40 basis points to Teleflex's total. So you'll start to see a portion of the conversion as we move through the latter part of the year, Cecilia, but the bulk of it you'll see arrive in 2022. And Tom could address some of the cadence of gross margins, if that's all right, Tom?
Tom Powell
executiveOkay. So regarding OEM and the other regions, there's a bit of a question there. When we look at the OEM side of things, the first quarter came in soft, then we had a good bounce back in the second quarter. Customers started to see procedures get better and started placing orders again, so trends were genuinely improving. We think that will keep going for the rest of the year. Now on the different geographies, our view has been consistent from the start: we expected North America, or the Americas, to be the first to bounce back, with Asia and EMEA coming after, and that is basically how it's unfolding. So relative to the first half, we look for every region to keep getting better in the back half, though the Americas may be somewhat stronger than a few of the others. And on the total gross margin, overall we're quite encouraged by the first half, which is what lets us raise the guidance. At the top end of that range, we sit at 59.75, a touch above where we stood in the first half. So what we're seeing gives us real encouragement, and we're cautiously optimistic looking at the back half.
Shagun Singh Chadha
analystI think the opening item concerns UroLift reimbursement. Would you discuss how the office rates might be introduced gradually? It seems likely that modifications to the Labor Code will take effect, yet these could be rolled out across a 4-year span. First, is that what you anticipate? Second, what effect do you foresee on procedures performed in the office setting, and on your capacity to shift them toward more lucrative settings as time goes on? Plus, regarding reductions in physician payment within the HOPD and ASC settings, I think that's roughly 6% on top of the reductions in the office setting. What effect do you anticipate that having on utilization in those settings? And I have a follow-up after that.
Liam Kelly
executiveAll right, Shagun; so our focus right now is squarely on the things within our control. Thus, we anticipate dedicating considerable time to collaborating with the main stakeholders throughout this comment period. Honestly, Shagun, I'd rather not begin speculating about the results, since the strategy would hinge on how the final ruling turns out. We'll keep engaging with CMS, a few of our industry bodies, patient advocacy organizations; and clearly, clinicians themselves are submitting comments to CMS concerning this reimbursement. As for the site of service, well, physicians do have a fair degree of flexibility there; and a number of urologists would have — some of their workload taking place in an office environment, some in an ASC, and it's quite common for even a portion to be in a hospital. That therefore gives the physician a certain degree of flexibility. My view is that CMS will welcome the comment period; and my view is that they will heed what each of these individuals says about this; concerning the ASC and the hospital reimbursement, that left us quite encouraged. On the whole, there's a 3% increase. Once more, this takes effect in January of 2022, Shagun. So in fact, nobody feels any impact until the year is over. And once more, it was broad based. So 600 procedures are affected by this, Shagun. So you can picture that a substantial number of comments will arrive during that comment period. And you had another question, Shagun, I think.
Shagun Singh Chadha
analystYeah. So regarding Q3 and the latter six months of 2021, I was hoping you might walk us through how the cadence shapes up. Q3 sales do seem to usually come in lower than Q2 levels, with EPS only slightly higher. So how do you view where consensus sits right now, and particularly for UroLift, I believe when I last looked, consensus was around 105?
Liam Kelly
executiveYeah. So matters are unfolding roughly the way we anticipated, Shagun. The Americas are driving this recovery, while Asia and Europe trail behind. Let me begin with Teleflex as a whole. So look, COVID hasn't disappeared, and we're watching things very carefully. And I, for whatever it's worth, want to add my own encouragement for everyone to please go get vaccinated. What matters most here is vaccination, since the second or third or fourth wave, whichever one we're in now, isn't affecting those who are vaccinated and isn't affecting regions where vaccination has happened; so we stay cautiously optimistic, and the trends from Q1 to Q2 have us very encouraged, and we anticipate Q2's stability will persist, which gave us the confidence to keep our full year revenue guidance in place even with the respiratory divestiture headwinds. Put another way, that would amount to a call up of between $28 million and $32 million on revenue and clearly a meaningful call up on our EPS too. So for Teleflex overall, my expectation is that our growth speeds up in the back half of the year compared with the first half. We grew 8.6% constant currency during the first half of the year. Taking the midpoint of our revenue guidance range, including the 1.6% divestiture headwind, that would suggest acceleration to 9.6% in the second half including that. If you take out the divestiture headwind, it's roughly 11.2% in the back half versus the 8.6%. So for the full year, we've effectively, as I mentioned, lifted our revenue guidance along with a strong EPS. And this marks the second quarter, once again, as investors are aware, where we've raised both our revenue and EPS; on UroLift, as I noted a few moments ago, I expect UroLift's absolute dollar values to rise in Q3 compared with Q2 and once more in Q4 compared with Q3 on that front. So thanks for the questions, Shagun.
Matthew O'Brien
analystI'll stay on UroLift too, so — let's just put all the questions out here. But Liam, you mentioned a proposal calling for a roughly 20% cut in the physician's office. If the final rule lands at a 10% reduction instead, would that force you to lower your price, and by how much, in that setting? And on top of that, if that turned out to be the case, do you figure clinicians would begin using fewer staples for each case?
Liam Kelly
executiveThe staple count wouldn't change at all, Matt, since there are 2 codes: 4 staples fall under one, and everything beyond that falls under the other. So it wouldn't — and the thing is — the reductions were set uniformly across every one of the categories. My sense is we'll evaluate our options after the final ruling comes down. Clearly, a 10% cut is far less severe than one of 20%; even so, you'd hope that common sense wins out. Consider what CMS did in the earlier ruling — they factored in a COVID impact of approximately 3.5%, and from what members of the key associations told us, they expected that piece to be taken out in this ruling and nothing beyond that. So we'll find out how it goes. That said, I don't anticipate a major effect, nor do I expect us to need to make any adjustments to the pricing structure overall, because we're strong across every care setting — the ASC, the office, the hospital, all of them. Which means we likely hold an edge, Matt, thanks to a degree of flexibility that other companies simply lack.
Matthew O'Brien
analystUnderstood. That's quite useful. Now, my next question concerns competition. I'd really like to hear your perspective regarding surgical robots used for BPH, along with what's good and bad about them. Do you believe that's something you'll ultimately need to offer?
Liam Kelly
executiveYeah, a product like that does exist. Matt, there's a PROCEPT robot on the market. It's picking up some usage. At the moment robots are viewed as somewhat attractive, yet it's genuinely making tarp. From the feedback we receive, it calls for a second procedure since heat isn't used. Instead, it employs a jet of water. When water is used, coagulation doesn't happen because there's no heat available to halt the bleeding. As a result, the surgeon must perform another procedure afterward to stop that bleeding. A number of urologists brought this up during a recent podium speech, and within their pivotal trial, several patients needed blood transfusions owing to problems with too much bleeding. So I believe it's — to me, it isn't truly a BPH treatment or a technology that will affect UroLift; our clinical data is extremely solid. Ours is a minimally invasive procedure, no catheter, no sexual dysfunction; plus we have a huge, huge bolus of trained physicians who are rolling out UroLift. So Matt, we know about it, but my direct answer to your question is that I don't view entering robotics as something we need to do.
Mike Matson
analystI've got a second question, this one about UroLift reimbursement. From what I recall, you mentioned that roughly 30% of procedures were taking place in the office setting. What I'm curious about, then, is how much growth occurred in that setting? In other words, does it contribute more heavily to growth, or has it roughly been expanding at the same pace as the remainder of the business?
Liam Kelly
executiveThanks for asking, Mike. It has been expanding at the same pace as the remainder of the business. When COVID hit, there was a modest shift toward performing more procedures in the office, but that is the sole effect you ought to factor in, and it remains very much at the same pace as the business's other sites of service.
Mike Matson
analystAlright, so the reimbursement amount wasn't really driving a meaningful push to perform additional procedures in that environment, or anything along those lines, correct?
Liam Kelly
executiveRight. In my view, UroLift made money across every site of service. And like I mentioned before, that gives us an edge that nearly all other treatment options lack; we've got adaptability while they don't. And once more, it accounts for 30% of the procedures, and roughly 70% of those — out of that 30%, Mike — is Medicare, Medicaid.
Mike Matson
analystAll right, understood. Then for my follow-up, I wanted to ask about pricing. I'm not sure whether you put a number on how much pricing helped. But taking a step back on pricing, considering the current state of the wider economy, with inflation and so on, do you feel it may be getting a bit — perhaps a bit simpler to secure price hikes on your products?
Liam Kelly
executiveMike, I've spent many years at this, and I can tell you, the number of times a customer has phoned me asking for a price increase can be counted on no hands, no fingers, no toes. So it's a hard environment, and we're constantly seeking pricing. But like I mentioned during the previous earnings call, we moved early on this. We expected there could be some shift in price momentum. And we had roughly 20 basis points of favorable pricing in Q1, which in fact picked up speed in Q2. We pursued some further opportunities in Q2, and we keep watching that very carefully; on the flip side, when it comes to inflation, we believe we've got that largely under control within our — especially within our global supply chain. Whatever inflation we encountered, we first noticed it in transportation last year. So that was already baked into our run rate. And we encountered some slight inflation in certain resins, but it was fairly — it's quite manageable, and we will more than offset that through genuinely favorable pricing and growing momentum during the quarter with that favorable pricing.
Anthony Petrone
analystAnthony, first off, I'd like to congratulate Larry on his new position with the company. There are a few things I'd like to ask about. First, Liam, it's really about the broader procedure backlog situation — there's been a lot of discussion about this during this earnings season. Obviously, it's difficult to put a number on it, but when you look across the portfolios, is there any way to get a sense of how much deferred procedure backlog remains out there, and maybe which segments stand to gain the most as we move toward the latter part of the year? I'll have one more question after that.
Liam Kelly
executiveLiam, thanks for giving Larry that recognition. We're glad to have him aboard the Teleflex ship. On the backlog question, honestly, it's tough for us to quantify as well. There must be a buildup of procedures out there, since for close to a year, hardly any procedures were being performed. My view is that whatever procedure backlog exists will hinge on the site of service and on customer confidence about returning. So again, coming back to the CMS decision I brought up, I don't think this would be the right moment for them to make the change they're discussing, because patients themselves view an office or an ASC setting as a far safer place to have a procedure done. And it's a lower-cost site of service for the person receiving it. That said, I'd assume there has to be a backlog — especially in our UroLift business, there has to be one in our surgical business, and there has to be one in our interventional business. Mapping it out is difficult for us. I don't believe we've seen much of it flow through the system yet, Anthony, because hospitals simply don't have that extra capacity, and they'll likely handle some of the more acute procedures first, and I can tell you we aren't factoring any significant backlog into our thinking for the back half of the year.
Anthony Petrone
analystAll right. For the follow-up, I'd like to ask about UroLift, and I'll also slip in one question about MANTA. Regarding UroLift, could you give us a baseline for the number of procedures that your active users perform each month? And what's the typical implant count? Our assumption is that it remains at 4 or 4.5 implants. Then for MANTA, since that was a standout quarter, can you provide some detail on whether that came from new centers, from share gain, or simply as a rebound from backlog?
Liam Kelly
executiveSure. Let me begin with UroLift. The typical figure remains at roughly 4.5 implants, and as we come out of COVID, we're seeing approximately 4 procedures per average urologist. As for MANTA, growth continues, and it was an excellent quarter. The procedures for MANTA are still coming predominantly from the TAVR segment. Roughly 84% of them occurred in TAVR during that quarter, which matches Q1, with about 11% in EVAR and a modest 4-ish percent in PVAT. So we keep training physicians. We're reaching more accounts. And Anthony, this is one of the areas where we'll direct some investment during the back half of the year, since we want to train additional interventionalists, and we view this as a future catalyst for Teleflex growth — good, solid, sustainable growth for a company like Teleflex. You should also expect that we'll add more feet on the street to conduct more training and onboard more docs at a quicker pace.
Richard Newitter
analystI had a few additional questions about UroLift. I realize it's receiving a great deal of focus, but I believe it matters. First, regarding cost. Liam, what choices do you have to vary pricing according to the site of care? Is there any mechanism involving rebates through which you might hold pricing at a single level in one setting while, if you needed to retain the physician, applying a reduction? Then I have one more question after that.
Liam Kelly
executiveCertainly, Rich. Naturally, our approach to pricing will be set after the ruling comes down in its final form. However, in response to what you asked, yes, we can be flexible depending on where the service is delivered and depending on the specific contracts that already exist. That means such flexibility stays available to us. As you're aware, cutting prices isn't something our company does and it never has been, nor do we plan to become that kind of company. Our anticipation is that we'll hold steady on the overall average selling price across every one of our product categories, though we do possess a degree of flexibility, to address your question in a straightforward way.
Richard Newitter
analystThat's useful. Then perhaps a couple of fast questions. Regarding the third-quarter remarks, particularly about UroLift, you're welcome to respond about the entire company too. If you examine the UroLift ramp, the consensus figure, I believe somebody cited $103 million, $104 million, representing a sequential gain from 92, which leaves a broad span between where consensus sits and what that might imply. I think it would help investors if you simply offered a sense of how it compares with consensus. Is it exactly right, perhaps somewhat cautious, or a bit too ambitious for the ramp? Any insight there would be useful. And while I have you, regarding Japan. Does the 30% figure for the back half of the year include anything from Japan? Could you clarify what you mean by modest? Also, if and when reimbursement approval comes through for Japan, how should we think about a year-one-style contribution scenario?
Liam Kelly
executiveRich, I'll start with Japan since I'm not going to speak to consensus. Regarding Japan, modest means modest, Rich. For UroLift in quarter 4, the dollar amount we have is very small. That market is worth $2 billion. The only ramp precedent available to us is what happened in the United States. And you should think of Japan as being about one-third the size of the U.S. market. Looking at the U.S. trajectory, the initial twelve months brought in $5 million, followed by $16 million, and after that we hit $50 million. Once that $50 million foundation was in place, growth sped up past $100 million, then $200 million, then $300 million, continuing upward from there. Japan's situation is different because it operates as a single-payer system, which works to our benefit — after securing reimbursement, we're able to offer the product across every site of service. That said, it's a market that tends to move cautiously. We've already pinpointed the 20 leading key opinion leaders to begin building adoption. The way things function in that country is very much structured by hierarchy. After securing those key opinion leaders—getting them trained and having them present from the podiums—the effect will begin to spread gradually to the rest of the urology practices. Our starting point will be the tertiary hospitals and the key thought leaders, and from there we'll expand. More specifics about the market sizes across Japan and the other geographies we plan to target will be shared when we hold our Investor Day toward the end of this year. What I can say is that we'll reach Japan ahead of any competitor. On that front, we hold a considerable lead over the market. We think we'll reach the China market long before any competitor that comes after us. That gives us a window to develop that market and establish this as the standard of care. One more advantage compared with the U.S.: as you know, the two competing products, Rezum and UroLift, entered the market at about the same time — Rezum actually came in a bit earlier. As for UroLift, rather than speak to the consensus, I'll just repeat what I said before, Rich: we expect growth in absolute dollars each quarter, with Q3 higher than Q2 and Q4 higher than Q3.
Matthew Mishan
analystMatt, stepping back for a broader view: why do you think CMS directed these adjustments at the physician office in particular? And then, for that 30% of procedures you mentioned, how realistic is a move from a physician office into an ASC setting?
Liam Kelly
executiveWell, Matt, one thing to keep front of mind — above all, a urologist owes a duty of care to the patient, and they'll act in the patient's best interest and choose the best procedure for that person. So the point worth flagging is this: UroLift is minimally invasive, delivers instant relief, causes no sexual dysfunction, and has very — essentially no side effects; and after the procedure, the patient won't need a catheter. That made it a simple call for the clinician to select UroLift ahead of any other technology, which explains why we hold the dominant position in this space. As for shifting the site of service, I don't believe we — once the final ruling comes down, I'm hopeful that could turn into a moot point, whether we're talking about moving the site of service from one area to another. As for what motivated CMS, honestly, at this stage it's hard for me to determine. Still, we'll engage with them, and in doing so, we'll clearly listen to whatever they tell us. That's what I said earlier. We have to grasp what their motivation was, since right now it isn't clear to us what prompted this change affecting 600 surgical procedures carried out in an office.
Matthew Mishan
analystUnderstood. Then for Tom, regarding the margin picture — I believe that represents a significant shift in the first half compared with what we had anticipated. Are you controlling expenses well? Is it product mix? Or does this reflect a structural gain toward those longer-term objectives you previously set on stronger sales?
Tom Powell
executiveI'd say, when we consider the improvement in margin within the guidance, what you're really asking is what's causing it — and yes, we clearly are keeping expenses and costs in check. But what I'd point to is that we experienced, I'd call it, extremely solid manufacturing efficiency across the first half of the year, and we anticipate that carrying into the back half. We've also observed many of the businesses bouncing back from the depressed levels they hit during COVID. And those operations that rebounded strongly happen to include several of our higher-margin brands. So our surgical, our interventional, interventional urology all trended upward in their recovery, and that contributed to driving the margin too. If you look at simply the first half versus second half, we do anticipate during the second half that incremental expense will come with operating the business, as we keep watching our business and really the industry go back to a more normalized condition; we expect our people to be traveling more, we expect to restart hiring, and so on. And so we will incur some additional operating expenses in the second half of the year compared with the first half. We also have some investment. As we said, we've placed some investment into the plan that's incremental relative to what we had before. And that sits behind UroLift as well as MANTA. So I'd say that on the whole, we're quite encouraged by the gross margin and its trajectory. And then given the success in the first half of the year, it gives us the chance to put a bit more investment into the back half.
Larry Keusch
executiveThanks, Dexter, and thanks to all of you who are with us on today's call; we appreciate it. That wraps up the Teleflex Inc. Second Quarter 2021 Earnings Conference Call. Take care.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.